CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection

BackgroundStable simultaneous knock down of the HIV-1 coreceptors CCR5 and CXCR4 is a promising strategy to protect cells from both R5 macrophage tropic and X4 T cell tropic as well as dual tropic viral infections. The potency of shRNAs in targeted gene silencing qualifies them as powerful tools for long term HIV gene therapy. Our previous work with a bispecific lentiviral vector containing CXCR4 and CCR5 shRNAs showed efficacy in down regulating both coreceptors and conferring viral resistance to both X4 and R5-tropic strains of HIV-1 in cultured cell lines. To extend these results to a stem cell gene therapy setting, here we show transduction of primary CD34+ hematopoietic progenitor cells to derive normal end stage cells that are resistant to HIV-1 infection.ResultsThe bispecific XHR lentiviral vector harboring CXCR4 and CCR5 shRNA expression cassettes was efficient in transducing CD34+ cells. The transduced cells gave rise to morphologically normal transgenic macrophages when cultured in cytokine media. There was a marked down regulation of both coreceptors in the stably transduced macrophages which showed resistance to both R5 and X4 HIV-1 strains upon in vitro challenge. Since off target effects by some shRNAs may have adverse effects on transgenic cells, the stably transduced macrophages were further analyzed to determine if they are phenotypically and functionally normal. FACS evaluation showed normal levels of the characteristic surface markers CD14, CD4, MHC class II, and B7.1. Phagocytic functions were also normal. The transgenic macrophages demonstrated normal abilities in up-regulating the costimulatory molecule B7.1 upon LPS stimulation. Furthermore, IL-1 and TNFα cytokine secretion in response to LPS stimulation was also normal. Thus, the transgenic macrophages appear to be phenotypically and functionally normal.ConclusionThese studies have demonstrated for the first time that a bispecific lentiviral vector could be used to stably deliver shRNAs targeted to both CCR5 and CXCR4 coreceptors into CD34+ hematopoietic progenitor cells and derive transgenic macrophages. Transgenic macrophages with down regulated coreceptors were resistant to both R5 and X4 tropic HIV-1 infections. The differentiated cells were also phenotypically and functionally normal indicating no adverse effects of shRNAs on lineage specific differentiation of stem cells. It is now possible to construct gene therapeutic lentiviral vectors incorporating multiple shRNAs targeted to cellular molecules that aid in HIV-1 infection. Use of these vectors in a stem cell setting shows great promise for sustained HIV/AIDS gene therapy.

[1]  J. Rossi,et al.  Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. , 2000, Antisense & nucleic acid drug development.

[2]  G. Stewart,et al.  A Human Immunodeficiency Virus Type 1 Isolate from an Infected Person Homozygous for CCR5Δ32 Exhibits Dual Tropism by Infecting Macrophages and MT2 Cells via CXCR4 , 2002, Journal of Virology.

[3]  P. Gilles,et al.  Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. , 2000, Virology.

[4]  D. Baltimore,et al.  Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Ben Berkhout,et al.  Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition , 2004, Journal of Virology.

[6]  S. Bartz,et al.  Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. , 1997, Virology.

[7]  B. Cullen,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Replication in Primary Macrophages by Using Tat- or CCR5-Specific Small Interfering RNAs Expressed from a Lentivirus Vector , 2003, Journal of Virology.

[8]  J. Rossi,et al.  Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy. , 2001, AIDS research and human retroviruses.

[9]  N. Yamamoto,et al.  High-efficiency transduction of human lymphoid progenitor cells and expression in differentiated T cells , 1997, Journal of virology.

[10]  Phillip D. Zamore,et al.  RNA Interference , 2000, Science.

[11]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[12]  Steven M. Wolinsky,et al.  The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.

[13]  J. Rossi,et al.  Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  M. Emerman,et al.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene , 1992, Journal of virology.

[15]  D. Strayer,et al.  Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV. , 2003, Oligonucleotides.

[16]  R. Bronson,et al.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Rossi,et al.  siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. , 2003, Anticancer research.

[18]  B. Clotet,et al.  Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication , 2002, AIDS.

[19]  I. Plavec,et al.  RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication , 1997, Journal of virology.

[20]  J. Yee,et al.  Design of HIV vectors for efficient gene delivery into human hematopoietic cells. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  J. Lisziewicz,et al.  Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Lehmann,et al.  The chemokine SDF1/CXCL12 and its receptor CXCR4 regulate mouse germ cell migration and survival , 2003, Development.

[23]  J. Rossi,et al.  Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  D. Weissman,et al.  Inhibition of HIV-1 Infection by Small Interfering RNA-Mediated RNA Interference1 , 2002, The Journal of Immunology.

[25]  Ki-Young Lee,et al.  Cloned zebrafish by nuclear transfer from long-term-cultured cells , 2002, Nature Biotechnology.

[26]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[27]  J. Lieberman,et al.  Sustained Small Interfering RNA-Mediated HumanImmunodeficiency Virus Type 1 Inhibition in PrimaryMacrophages , 2003, Journal of Virology.

[28]  M. Malim,et al.  Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication , 1992, The Journal of experimental medicine.

[29]  G. Hannon.  RNA interference : RNA , 2002 .

[30]  B. Cullen,et al.  Potent and Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by RNA Interference , 2002, Journal of Virology.

[31]  L. Ailles,et al.  HIV-1-derived lentiviral vectors. , 2002, Current topics in microbiology and immunology.

[32]  J. Rossi,et al.  A nucleolar TAR decoy inhibitor of HIV-1 replication , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Funke,et al.  Tissue-Resident Macrophages Are Productively Infected Ex Vivo by Primary X4 Isolates of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[34]  B. Ramratnam,et al.  Human Immunodeficiency Virus Type 1 Escape from RNA Interference , 2003, Journal of Virology.

[35]  John Rossi,et al.  Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  M. Stevenson,et al.  Modulation of HIV-1 replication by RNA interference , 2002, Nature.

[37]  B. Berkhout,et al.  Inhibition of virus replication by RNA interference. , 2003, Journal of biomedical science.

[38]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[39]  R. Akkina,et al.  HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector , 2005, AIDS research and therapy.

[40]  R. Morgan,et al.  Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes. , 2002, AIDS patient care and STDs.

[41]  U Klingmüller,et al.  Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors , 2002, Gene Therapy.

[42]  B. Cullen,et al.  Chemokine receptors and human immunodeficiency virus infection. , 1998, Frontiers in bioscience : a journal and virtual library.

[43]  J. Rossi,et al.  RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  S. Ding,et al.  A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins. , 2002, Frontiers in bioscience : a journal and virtual library.

[45]  J. Lieberman,et al.  siRNA-directed inhibition of HIV-1 infection , 2002, Nature Medicine.

[46]  P. Sharp,et al.  RNA interference--2001. , 2001, Genes & development.

[47]  D. Kohn,et al.  Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture , 1996, Journal of virology.

[48]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[49]  A. Telenti,et al.  Protection from HIV-1 Infection of Primary Cd4 T Cells by Ccr5 Silencing is Effective for the Full Spectrum of Ccr5 Expression , 2002, Antiviral therapy.

[50]  V. Planelles,et al.  Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. , 2003, AIDS research and human retroviruses.

[51]  Ali Ehsani,et al.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells , 2002, Nature Biotechnology.

[52]  A. Banerjea,et al.  Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. , 2003, Oligonucleotides.

[53]  Tyra G. Wolfsberg,et al.  Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Pomerantz,et al.  Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4 , 2004, Gene Therapy.